Yoshiki Sakai Selected Research

Epoprostenol (Prostacyclin)

12/2021	New regional drug delivery system by direct epicardial placement of slow-release prostacyclin agonist promise therapeutic angiogenesis in a porcine chronic myocardial infarction.
11/2021	Combined administration of laminin-221 and prostacyclin agonist enhances endogenous cardiac repair in an acute infarct rat heart.
1/2021	Innovative therapeutic strategy using prostaglandin I2 agonist (ONO1301) combined with nano drug delivery system for pulmonary arterial hypertension.
12/2020	Synthetic Prostacyclin Agonist Attenuates Pressure-Overloaded Cardiac Fibrosis by Inhibiting FMT.
9/2020	Administration of Slow-Release Synthetic Prostacyclin Agonist Promoted Angiogenesis and Skeletal Muscle Regeneration for Limb Ischemia.
6/2019	Prostacyclin Analogue-Loaded Nanoparticles Attenuate Myocardial Ischemia/Reperfusion Injury in Rats.
1/2019	Single injection of sustained-release prostacyclin analog ONO-1301-MS ameliorates hypoxic toxicity in the murine model of amyotrophic lateral sclerosis.
1/2018	A prostacyclin agonist and an omental flap increased myocardial blood flow in a porcine chronic ischemia model.
7/2015	A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and/or regeneration in the damaged heart.
1/2015	ONO-1301, a sustained-release prostacyclin analog, ameliorates the renal alterations in a mouse type 2 diabetes model possibly through its protective effects on mesangial cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshiki Sakai Research Topics

Disease

17	Fibrosis (Cirrhosis) 01/2021 - 07/2009
8	Ischemia 09/2020 - 07/2009
5	Infarction (Infarctions) 12/2021 - 03/2012
5	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 03/2014 - 12/2009
4	Cardiomyopathies (Cardiomyopathy) 12/2021 - 12/2009
4	Myocardial Ischemia (Ischemic Heart Diseases) 06/2019 - 07/2009
3	Myocardial Infarction 12/2021 - 01/2013
3	Wounds and Injuries (Trauma) 08/2021 - 06/2012
3	Ureteral Obstruction 10/2016 - 06/2012
3	Heart Failure 07/2015 - 08/2013
3	Hypertrophy 01/2015 - 10/2012
3	Pulmonary Hypertension 06/2012 - 12/2005
2	Proteinuria 08/2021 - 10/2012
2	Hypertension (High Blood Pressure) 08/2021 - 10/2012
2	Pulmonary Arterial Hypertension 01/2021 - 01/2013
2	Reperfusion Injury 06/2019 - 01/2012
2	Chronic Renal Insufficiency 02/2016 - 01/2015
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2021
1	Rodent Diseases 08/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Breast Neoplasms (Breast Cancer) 01/2021
1	Neoplasms (Cancer) 01/2021
1	Chronic Limb-Threatening Ischemia 09/2020
1	Arteriosclerosis Obliterans 09/2020
1	Neuroinflammatory Diseases 01/2019
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2019
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019
1	Disease Progression 01/2019
1	Kidney Diseases (Kidney Disease) 10/2016
1	Acute Kidney Injury (Acute Renal Failure) 12/2015
1	Critical Illness (Critically Ill) 12/2015
1	Inflammation (Inflammations) 07/2015
1	Hyperglycemia 01/2015
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2015
1	Obesity 01/2015
1	Type 2 Diabetes Mellitus (MODY) 01/2015
1	Albuminuria 01/2015
1	Chronic Pancreatitis 05/2014
1	Myocarditis (Carditis) 01/2013
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2013

Drug/Important Bio-Agent (IBA)

26	Epoprostenol (Prostacyclin)FDA LinkGeneric 12/2021 - 12/2005
18	ONO 1301IBA 12/2020 - 12/2005
8	ThromboxanesIBA 01/2013 - 12/2005
7	Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA 08/2021 - 10/2012
7	CollagenIBA 08/2013 - 07/2009
6	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 12/2013 - 12/2009
5	camostatIBA 08/2021 - 07/2013
4	CytokinesIBA 12/2021 - 08/2013
4	Therapeutic UsesIBA 07/2015 - 06/2012
3	Pharmaceutical PreparationsIBA 01/2021 - 08/2012
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2012
2	ameroidIBA 12/2021 - 01/2018
2	Serine Proteases (Serine Protease)IBA 08/2021 - 10/2016
2	SaltsIBA 10/2016 - 10/2012
2	Adenine FDA LinkGeneric 02/2016 - 01/2015
2	ProstaglandinsIBA 12/2015 - 01/2006
2	Messenger RNA (mRNA)IBA 01/2015 - 01/2013
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2013 - 12/2009
2	Connective Tissue Growth FactorIBA 07/2013 - 01/2013
2	Hydroxyproline (4 Hydroxyproline)IBA 07/2013 - 01/2006
2	AntibodiesIBA 08/2012 - 06/2012
2	Polyglactin 910IBA 03/2012 - 01/2012
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2009 - 07/2009
2	MonocrotalineIBA 01/2008 - 12/2005
1	Ligases (Synthetase)IBA 01/2021
1	Nanoparticle Drug Delivery SystemIBA 01/2021
1	SolutionsIBA 06/2019
1	Vasodilator Agents (Vasodilators)IBA 01/2019
1	Glutamic Acid (Glutamate)FDA Link 01/2019
1	Fibrinolysin FDA Link 10/2016
1	AldosteroneIBA 10/2016
1	Telmisartan (Micardis)FDA Link 02/2016
1	Indicators and Reagents (Reagents)IBA 07/2015
1	AntioxidantsIBA 01/2015
1	Collagen Type IV (Type IV Collagen)IBA 01/2015
1	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2015
1	dibutyldichlorotinIBA 05/2014
1	Brain Natriuretic Peptide (Natrecor)FDA Link 03/2014
1	salicylhydroxamic acid (SHAM)IBA 03/2014
1	Biological ProductsIBA 03/2014
1	Cytoskeletal ProteinsIBA 12/2013
1	Sarcoglycans (beta Sarcoglycan)IBA 12/2013
1	atelocollagenIBA 12/2013
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 07/2013
1	Transforming Growth Factors (Transforming Growth Factor)IBA 07/2013
1	Plasminogen Activators (Plasminogen Activator)IBA 07/2013
1	Myosins (Myosin)IBA 01/2013
1	Neutralizing AntibodiesIBA 01/2013
1	Synthetic Prostaglandins (Prostaglandin Analogues)IBA 01/2013
1	Collagen Type I (Type I Collagen)IBA 01/2013
1	Collagen Type III (Type III Collagen)IBA 01/2013
1	CreatinineIBA 10/2012
1	nephrinIBA 10/2012

Therapy/Procedure

4	Therapeutics 01/2019 - 12/2013
3	Subcutaneous Injections 01/2015 - 01/2012
2	Microspheres (Microsphere) 03/2012 - 01/2012
1	Nanospheres 01/2021
1	Cell- and Tissue-Based Therapy (Cell Therapy) 09/2020
1	Oral Administration 01/2013
1	Nephrectomy 10/2012